Should you buy ADMA Biologics (ADMA)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
ADMA currently trades below the base anchor, in the lower half of the engine methodology range.
Engine methodology range — mechanically derived from pipeline gate outputs + peer-multiple inputs. Not an analyst price target. JSON-LD emission gated pending counsel review.
What the engine is tracking
- Deep Valuation Discount↓Deteriorating
- Superior Returns Versus Peers→Stable
- Fcf Conversion Shortfall→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Deep Valuation Discount
Trip ifForward P/E rises above 20x, indicating the deep valuation discount has been fully re-rated and the original entry thesis is consumed.
- P2Superior Returns Versus Peers
Trip ifReturn on equity falls below 20% for 2 consecutive quarters, indicating the return advantage versus peers has narrowed materially from the current 43%.
- P3Fcf Conversion Shortfall
Trip ifFree cash flow conversion rises above 80% of net income for 2 consecutive quarters, confirming the earnings-quality concern has resolved.
- P4Trend Breakdown With Improving Signals
Trip ifRSI falls below 40 and on-balance volume declines for 6 consecutive weeks, confirming the recovery setup has failed and the downtrend has resumed.
- P5News Gate And Earnings Miss
Trip ifEPS surprise exceeds 5% for 2 consecutive quarters with no new material news risks flagged, confirming the cautionary setup has fully cleared.
How the engine reached this verdict
TrendMatrix's engine output for ADMA Biologics Inc (ADMA) is HOLD_IF_HOLDING with medium conviction, score 6.2/10 at $9.52. The C-path quality+value combination cleared its gates — quality 8.2 and value 8.2 — with 5.03 asymmetric R:R supporting the read.
ADMA Biologics Inc (ADMA) sits at overall score 6.2/10 with no actively-failing gates (strongest-cleared: MOMENTUM:6.1>=5.5). HOLD flips toward BUY_WAIT when a positive-conviction path (C-quality or D-momentum) triggers; toward SELL when any of the currently-passing gates drop below threshold or three+ dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around $9.25 with a technical stop near $8.60 for existing positions. Asymmetric R:R is 5.03, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 1.2% of portfolio at this asymmetry level (high-conviction tier).
On the bull side: V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF); Sector modifier (Healthcare): +0.5; High-quality business. On the bear side: Weak growth; Below 200-MA, MA slope -8.2%/30d (confirmed downtrend). Active engine warnings: RISK-OFF: SMALL-cap BUY_NOW needs quality>=8.5 or MoS>=50%, News gate: 0 distinct critical events (0 MATERIAL_RISK articles).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ADMA — 10-dimension breakdown →
Bull case
- ▸V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸High-quality business
Bear case
- ▸Weak growth
- ▸Below 200-MA, MA slope -8.2%/30d (confirmed downtrend)